| Literature DB >> 25962509 |
Catherine J Reynolds1, Malcolm J W Sim2, Kathryn J Quigley3, Daniel M Altmann4, Rosemary J Boyton5.
Abstract
BACKGROUND: Multiple sclerosis is generally considered an autoimmune disease resulting from interaction between predisposing genes and environmental factors, together allowing immunological self-tolerance to be compromised. The precise nature of the environmental inputs has been elusive, infectious agents having received considerable attention. A recent study generated an algorithm predicting naturally occurring T cell receptor (TCR) ligands from the proteome database. Taking the example of a multiple sclerosis patient-derived anti-myelin TCR, the study identified a number of stimulatory, cross-reactive peptide sequences from environmental and human antigens. Having previously generated a spontaneous multiple sclerosis (MS) model through expression of this TCR, we asked whether any of these could indeed function in vivo to trigger CNS disease by cross-reactive activation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25962509 PMCID: PMC4432996 DOI: 10.1186/s12974-015-0313-9
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Peptide sequence and origin
|
|
|
|
|
|
|---|---|---|---|---|
|
|
|
|
|
|
| FGVKI | 1721 | A |
| UDP-N-Acetylglucosamine pyrophosphorylase |
| VFGN | 1525 | B |
| Hypothetical protein |
| AAQRI | 1658 | C |
| Hypothetical protein |
| L | 1695 | D |
| Exonuclease ABC C subunit domain protein |
| RLS | 1569 | E |
| Spore germination protein |
| AAQN | 1640 | F |
| Hypothetical protein MPH |
| STAR | 1706 | G |
| Hypothetical protein |
| DVSK | 1564 | H |
| ABC transporter |
| HRAKL | 1783 | I |
| Aldo/keto reductase |
| YKHKI | 1832 | J |
| Hypothetical protein DFA |
| IEAAI | 1595 | K |
| Component of TOM complex |
| SSARL | 1636 | L |
| Hypothetical protein |
| KDFTFVCPTEIVEFAKLAKQ | 2315 | Bp |
| AhpC (51-70) |
aBold type face indicates sequence homology with MBP85-99..Data in this table are based on information within reference 7.
Figure 1T cell assays show the relative functional avidity of environmental ligands. (A-L) Unprimed splenocytes from previously described HLA-DR15 and TCR transgenics carrying an anti-MBP (85-99) specific TCR (clone Ob1.A12) on an HLA-DR1501/Aβo background (n = 6) were cultured in triplicate on precoated IFNγ ELISpot plates with 0.25, 2.5, or 25 μg/ml of each of the 12 test peptides, MPB 85-99, and a negative control peptide (HLA-DR1501 binding peptide from Burkholderia pseudomallei, AhpC, BPSL2096 (51-70) KDFTFVCPTEIVEFAKLAKQ which stimulates potent CD4 T cell responses in HLA-DR1501/Aβo transgenic mice [11]). Cells were cultured for 72 h before plate development. Data are expressed as SFC/106 splenocytes and shown as mean values ± SEM. In each case, MBP 85-99 positive control peptide is indicated as closed squares, test peptide as closed circles, and negative control peptide as closed triangles. Test peptide identities were as follows: (A) Encephalitozoon romaleae, FGVKIHFFKQRNSL; (B) Chlorobium chlorochromatii CaD3, VFGNVHFFKNTGSA; (C) Rhodococcus sp. AW25MO9, AAQRIHFFKNLSLL; (D) Clostridium papyrosolvens, LNKNIHFFKNLPLP; (E) Anoxybacillus flavithermus, RLSVVHFLRANAVS; (F) Macrophomina phaseolina MS6, AAQNVHFWKALNQL; (G) Emiliania huxleyi CCMP1516, STARVHFWRSRSSE; (H) Rhizobium leguminosarum, DVSKVHFFKGNGQT; (I) Runella slithyformis DSM 19594, HRAKLHFFKDENLK; (J) Dictyostelium fasciculatum, YKHKIHFFKNEVLE; (K) Ogataea parapolymorpha DL-1, IEAAIHFYKGLAVY; (L) Myxococcus stipitatus DSM14675, SSARLHFFRALPHP.
Figure 2Induction of autoimmune paralysis in TCR transgenic multiple sclerosis model by a cross-reactive Dictyostelium slime mold peptide. Previously described HLA-DR15 and TCR transgenics carrying an anti-MBP (85-99) specific TCR (clone Ob1.A12) and HLA-DR1501, Ao were used to test the encephalitogenic capacity of test peptides. Young male mice received 300 μg peptide subcutaneously in supplemented CFA at day 0 and 50 μg peptide subcutaneously in CFA at day 6. Pertussis toxin at a dose of 200 ng intraperitoneally was administered on days 0, 2, 6, and 8. Mice were scored daily for signs of neurological disease using an established disease score scale according to the following criteria: 0, normal; 1, limp tail; 2, impaired righting reflex or waddling gait; 3, partial hind limb paralysis; 4, total hind limb paralysis; 5, total limb paralysis. HLA-DR15 and TCR transgenics carrying the anti-MBP (85-99)-specific TCR (clone Ob1.A12) and HLA-DR1501, Ao were administered MBP 85-99 peptide (closed circles, n = 6), Dictyostelium fasciculatum YKHKIHFFKNEVLE peptide (closed squares, n = 6), Emiliania huxleyi CCMP1516 STARVHFWRSRSSE peptide (closed triangles, n = 6), control peptide, Burkholderia pseudomallei AhpC (51-70) KDFTFVCPTEIVEFAKLAKQ (closed diamonds, n = 6), C57BL/6 mice administered MBP 85-99 peptide (open circles, n = 5), Emiliania huxleyi CCMP1516 STARVHFWRSRSSE peptide (open triangles, n = 5), Dictyostelium fasciculatum YKHKIHFFKNEVLE peptide (open squares, n = 5), and Burkholderia pseudomallei AhpC (51-70) KDFTFVCPTEIVEFAKLAKQ (open diamonds, n = 5). MBP, myelin basic protein.